Skip to content
Head to head

Zai Lab vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ZLAB · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

ZLAB +0.5%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
ZLABVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price21.03515.02
Change today-4.06%-1.08%
1-year return+4.1%+22.0%
Market cap$2.36B$130.58B
52-week range15.96 – 29.02412.27 – 568.67
Valuation
P/E (TTM)-11.6833.14
P/E percentile, own 5-yr range15th99th
P/B4.206.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.6015.32
Net profit (TTM)$-179.91M$3.88B
Revenue (TTM)$441.73M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-6.8%+11.8%
Gross margin54.7%85.5%
Operating margin-61.7%33.1%
Net margin-44.9%30.7%
Free cash flow (TTM)$-197.16M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership70.9%96.8%
Insider activity (12mo)21 buy / 29 sell28 buy / 22 sell
Short interest (% of float)7.2%1.9%
Analyst consensus100% buy (3)95% buy / 5% hold (21)
Analyst price target$39 (+87%)$624 (+21%)
StockVane view
StockVane Quant RatingD (43)C (68)
Company
Employees1,7846,400
Founded20141989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.